Compare Dyne Therapeutics Inc. Common Stock (DYN) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs ProShares UltraPro Short QQQ ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while ProShares UltraPro Short QQQ ETF trades at $37.19 (market cap $2.13B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and ProShares UltraPro Short QQQ ETF is more actively traded (37,167,173 versus 2,195,902). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| DYN | SQQQ | |
|---|---|---|
Market Cap | $2.81B | $2.13B |
Volume | 2,195,902 | 37,167,173 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.78 | $89.43 |
52-Week Low | $14.60 | $31.83 |
Typical Hold Time | 0 Days | 12 Days |
Enterprise Value | $2.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SQQQ, the ProShares UltraPro Short QQQ ETF, is currently trading at $33.98, up 1.04% on the day. The technical outlook is bearish, with moving averages signaling a downtrend and oscillators neutral. As a 3x leveraged inverse ETF, its performance is directly tied to declines in the Nasdaq-100 index. Recent news highlights its use as a hedging tool against tech sector weakness, with articles discussing its potential benefits amid concerns over the AI-fueled tech rally.
The outlook for SQQQ is inherently tied to market sentiment toward the Nasdaq-100. It presents a high-risk, tactical opportunity for investors seeking to profit from or hedge against a downturn in major technology stocks. Key risks include the daily reset mechanism of leveraged ETFs, which can lead to decay in volatile markets, and the potential for rapid losses if the tech rally resumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
